Wherein R1, L1, R3, R4, Cy, L2 and R5 are as defined herein. Novel imidazolopyridines according to Formula I, able to inhibit JAK are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.其中R1、L1、R3、R4、Cy、L2及R5如本文所定義。本發明揭示能夠抑制JAK之根據式I之新穎咪唑并吡啶，該等化合物可製備成醫藥組合物形式，且可用於預防及治療包括人類在內之哺乳動物的多種病況，該等病況之非限制性實例包括過敏性或發炎病況、自體免疫疾病、增生性疾病、移植排斥反應、涉及軟骨代謝減弱之疾病、先天性軟骨畸形，及/或與IL6或干擾素分泌過多有關的疾病。
